<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tinea capitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tinea capitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tinea capitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Treat, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H949998161"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tinea capitis is a fungal infection of the scalp that most often presents with pruritic, scaling areas of hair loss. <em>Trichophyton </em>and <em>Microsporum</em> species of dermatophyte fungi are the major causes of tinea capitis. The infection is often contracted from another human or an animal through direct contact.</p><p>Tinea capitis primarily occurs in children. The most common clinical findings are single or multiple scaly patches with alopecia and patches of alopecia with black dots at follicular orifices that represent broken hairs  (<a class="graphic graphic_picture graphicRef86686 graphicRef101630 graphicRef101858 graphicRef101271 graphicRef101859 graphicRef86628" href="/z/d/graphic/86686.html" rel="external">picture 1A-F</a>). Other presentations include widespread scaling with subtle hair loss, a boggy edematous painful plaque called a kerion  (<a class="graphic graphic_picture graphicRef86627" href="/z/d/graphic/86627.html" rel="external">picture 2</a>), and favus, which characteristically exhibits multiple cup-shaped, yellow crusts (scutula)  (<a class="graphic graphic_picture graphicRef101861" href="/z/d/graphic/101861.html" rel="external">picture 3</a>).</p><p>Oral antifungal therapy is the primary treatment for tinea capitis. Patients usually respond well to treatment.</p><p>The clinical features, diagnosis, and management of tinea capitis will be reviewed here. Other dermatophyte infections are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>.)</p><p class="headingAnchor" id="H949998167"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Tinea capitis is a common disorder. Children, particularly prepubertal children, are most likely to develop tinea capitis. Some studies have identified higher prevalences in male children than in female children [<a href="#rid1">1-5</a>]; however, other studies have not corroborated this finding [<a href="#rid6">6</a>]. Occasionally, adults develop tinea capitis [<a href="#rid7">7-11</a>].</p><p>Tinea capitis occurs worldwide with prevalences that vary geographically and demographically. Studies in the United States have revealed that tinea capitis is most common in African American children [<a href="#rid1">1,12</a>]. The reason for this is unknown. Theories to explain this observation have included effects of socioeconomic factors or differences in genetic susceptibility [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H420839731"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Tinea capitis is a dermatophyte infection. Dermatophytes are filamentous fungi in the genera <em>Trichophyton</em>, <em>Microsporum</em>,<em> </em>and<em> Epidermophyton</em> that infect keratinized tissue of skin, hair, or nails. Organisms in the <em>Trichophyton</em> and <em>Microsporum</em> genera generally cause tinea capitis. Tinea capitis due to <em>Epidermophyton</em> species is rare [<a href="#rid13">13</a>].</p><p>Dermatophytes are divided into anthropophilic (human), zoophilic (animal), and geophilic (soil) fungi. Anthropophilic and zoophilic dermatophytes are the most common causes of tinea capitis. Examples of dermatophyte species associated with tinea capitis include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anthropophilic</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton</em> <em>tonsurans</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton mentagrophytes</em> var. <em>interdigitale</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton violaceum</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton soudanense</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton</em> schoenleinii</p><p class="bulletIndent2"><span class="glyph">•</span><em>Microsporum audouinii</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Epidermophyton floccosum</em> (rare) </p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton rubrum</em> (rare)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zoophilic</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Microsporum canis</em> </p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton verrucosum</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton equinum</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Microsporum nanum</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Trichophyton</em> species of <em>Arthroderma benhamiae</em> [<a href="#rid14">14</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geophilic</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Microsporum gypseum</em></p><p class="bulletIndent2"><span class="glyph">•</span><em>Microsporum fulvum</em></p><p></p><p>The likelihood that a particular dermatophyte is the cause of tinea capitis varies geographically and evolves over time. In the United States and the United Kingdom, <em>T. tonsurans</em> has replaced <em>M. canis</em> as the most common causative organism [<a href="#rid1">1,15</a>]. <em>T. tonsurans</em> is also the predominant cause of tinea capitis in Canada, Brazil, France, and Japan [<a href="#rid16">16</a>]. <em>M. canis </em>remains a primary cause of tinea capitis in central and southern Europe, Russia, Australia, and China; however, shifts in the predominating cause of tinea capitis to <em>T. violaceum</em> or other organisms have been noted in some areas [<a href="#rid4">4,6,17</a>]. <em>M. audouinii</em> and <em>T. soudanense</em> are primary causes of tinea capitis in West Africa [<a href="#rid2">2,3</a>]. <em>T. verrucosum</em> is a common cause of tinea capitis in Turkey [<a href="#rid16">16</a>].</p><p>Whether nondermatophyte fungi and yeasts may also cause tinea capitis is uncertain. (See <a class="local">'Culture'</a> below.)</p><p class="headingAnchor" id="H420839737"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Tinea capitis is acquired through contact of the scalp with the causative dermatophyte. Acquisition of the fungus may result from direct contact with an infected individual or animal or from contact with a contaminated object (eg, comb, brush, or hat). Contact with asymptomatic carriers of causative organisms is an additional mode of transmission that may play an important role in recurrences of tinea capitis and tinea corporis [<a href="#rid18">18</a>]. (See <a class="local">'Management of close contacts'</a> below and <a class="local">'Treatment failure'</a> below.)</p><p>Once the dermatophyte comes in contact with the stratum corneum on the scalp, the establishment of infection is mediated by a variety of factors. As an example, mannan glycoproteins in dermatophyte cell walls promote adherence of dermatophytes to keratin-containing host tissue [<a href="#rid19">19</a>]. In addition, production of proteolytic enzymes, such as keratinase, by the dermatophytes enables invasion of the cytokeratin-containing tissues of the skin and hair [<a href="#rid19">19</a>]. The infection progresses from the stratum corneum of the epidermis, extending down the follicle and to the hair. Biofilms can form, which may make therapy more difficult [<a href="#rid20">20</a>].</p><p>Dermatophyte infection of the hair may present in three forms, <strong>endothrix</strong> infection, <strong>ectothrix</strong> infection, and <strong>favus</strong>. In endothrix infections, arthroconidia (fungal spores) are found within the hair shaft on direct microscopic examination. Common examples include <em>T. tonsurans, T. violaceum</em>,<em> and T. soudanense</em> infections. In ectothrix infections, arthroconidia primarily surround the outside of the hair shaft. Dermatophytes often associated with ectothrix infections include <em>T. verrucosum</em>, <em>M. canis, M. audouinii</em>, <em>M. nanum</em>,<em> and M. gypseum</em>. Favus is a unique presentation in which hyphae and air spaces are found within hair shafts. (See <a class="local">'Potassium hydroxide preparation'</a> below.)</p><p>The innate immune system likely plays a significant role in host defense against dermatophyte infection. An in vitro study evaluating the role of inflammasomes, components of the innate immune system, found evidence to suggest that the NLRP3 inflammasome plays an important role in host defense against <em>M. canis</em> infection [<a href="#rid21">21</a>].</p><p>The reasons for the predominance of tinea capitis in children are not well understood. Proposed theories to explain the infrequency in adults include effects related to the fungistatic properties of short- and medium-chain fatty acids in postpubertal sebum and the colonization of adults by commensal yeasts, such as <em>Pityrosporum</em>, that may inhibit infection with dermatophytes [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H949998211"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Tinea capitis may present with a variety of clinical features. There are five major clinical variants of tinea capitis as well as an asymptomatic carrier state. The causative organism and the host immune response to infection influence the clinical presentation.</p><p class="headingAnchor" id="H1140644340"><span class="h2">Clinical variants</span><span class="headingEndMark"> — </span>The most common clinical manifestations of tinea capitis are the development of scaly patches with alopecia and patches of alopecia with visible black dots. Diffuse scalp scaling with subtle hair loss, kerion, and favus are additional clinical variants. Pruritus is a common associated symptom in the various presentations of tinea capitis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scaly patches with alopecia </strong>– Single or multiple scaly patches with hair loss are a common presentation of ectothrix infections (eg, <em>M. canis</em>)  (<a class="graphic graphic_picture graphicRef86686 graphicRef101630 graphicRef101858 graphicRef101271 graphicRef101859" href="/z/d/graphic/86686.html" rel="external">picture 1A-E</a>). Individual patches are often a few centimeters to several centimeters in diameter. The patches enlarge centrifugally over the course of weeks to months. Erythema may be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patches of alopecia with black dots </strong>–<strong> </strong>Endothrix infections may present with manifestations often referred to as "black dot tinea capitis." Multiple black dots, which represent the distal ends of hairs that have broken at the surface of the scalp, are present at follicular orifices within areas of alopecia  (<a class="graphic graphic_picture graphicRef86628" href="/z/d/graphic/86628.html" rel="external">picture 1F</a>). The broken hairs are a result of weakening of the hair shaft secondary to the endothrix infection. The alopecic areas may be single or multiple and typically range from a few centimeters to several centimeters in diameter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Widespread scaling with subtle hair loss </strong>– Tinea capitis may exhibit diffuse scaling on the scalp without clear areas of alopecia  (<a class="graphic graphic_picture graphicRef101860" href="/z/d/graphic/101860.html" rel="external">picture 4</a>). This presentation may closely resemble seborrheic dermatitis and may be due to unknown host factors leading to less hair loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kerion</strong> – Kerion is a severe manifestation of tinea capitis resulting from an intense immune response to the infection. Kerion is characterized by the development of an inflammatory plaque with pustules, thick crusting, and/or drainage  (<a class="graphic graphic_picture graphicRef86627" href="/z/d/graphic/86627.html" rel="external">picture 2</a>).<strong> </strong>A suppurative folliculitis may be the initial presentation [<a href="#rid23">23</a>]. Tenderness or pain is often present.</p><p></p><p class="bulletIndent1">Kerions appear most commonly in children ages 5 to 10 and are rare in infancy [<a href="#rid24">24</a>]. Kerion is most often caused by a zoophilic dermatophyte; however, anthropophilic fungi can also cause a kerion. Persistent kerion can lead to scarring alopecia [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favus</strong> – Favus is a unique clinical presentation of tinea capitis resulting from infection with <em>T. schoenleinii</em> (and rarely other dermatophytes). In favus, perifollicular erythema progresses to the characteristic development of cup-shaped, yellow crusts called scutula  (<a class="graphic graphic_picture graphicRef101861" href="/z/d/graphic/101861.html" rel="external">picture 3</a>) [<a href="#rid26">26</a>]. The scutula contain fungi, neutrophils, dried serum, and epidermal cells. Scutula eventually coalesce to form adherent masses above areas of severe alopecia. There may be an associated unpleasant odor. The intense inflammation can result in permanent scarring. If untreated, favus may persist indefinitely [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H1140644322"><span class="h2">Associated findings</span><span class="headingEndMark"> — </span>Patients with tinea capitis may exhibit associated clinical findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cervical lymphadenopathy </strong>– Palpable cervical lymphadenopathy is a frequent finding in patients with tinea capitis, particularly when clinical signs of inflammation are present  (<a class="graphic graphic_picture graphicRef101857" href="/z/d/graphic/101857.html" rel="external">picture 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatophytid reactions </strong>– Autoeczematization reactions (id reactions) are secondary dermatitic eruptions that occur in association with a localized inflammatory skin disorder. The term dermatophytid reaction is used to refer to autoeczematization reactions that occur in association with dermatophyte infections. The pathogenesis may involve an immune reaction to fungal antigens, such as a delayed-type hypersensitivity response.</p><p></p><p class="bulletIndent1">Dermatophytid reactions often follow the onset of antifungal therapy, but may also precede treatment [<a href="#rid27">27</a>]. Patients develop a widespread pruritic eczematous eruption characterized by erythematous, scaly papules  (<a class="graphic graphic_picture graphicRef63421" href="/z/d/graphic/63421.html" rel="external">picture 6</a>). Involvement of the head, neck, trunk, or extremities is common. Dermatophytid reactions are managed with treatment of the underlying fungal infection as well as emollients, oral antihistamines, or topical corticosteroids as needed [<a href="#rid27">27</a>]. Oral corticosteroids are reserved for severe cases. (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Id reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– Infrequently, erythema nodosum occurs in association with kerion [<a href="#rid28">28-30</a>]. (See  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a>.)</p><p></p><p class="headingAnchor" id="H949998253"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histopathologic features of tinea capitis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fungal elements (arthroconidia or hyphae) within or surrounding hair shafts</p><p class="bulletIndent1"><span class="glyph">●</span>Perifollicular mononuclear infiltrate in the dermis</p><p class="bulletIndent1"><span class="glyph">●</span>Multinucleated giant cells in the dermis (in cases where the hair follicle is disrupted)</p><p></p><p>The fungi can be highlighted with periodic acid-Schiff (PAS) or Grocott's methenamine silver (also called Gomori's methenamine silver or GMS) stains.</p><p>Biopsies of kerions will exhibit an inflammatory reaction with a neutrophilic, granulomatous, or mixed dermal infiltrate [<a href="#rid23">23</a>]. Fungi may be difficult to identify due to the intensity of the inflammatory reaction [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H949998259"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Tinea capitis should be strongly considered in children presenting with scale and hair loss on the scalp, particularly if cervical lymphadenopathy is present. Because the diagnosis is infrequent in adults, a higher index of suspicion is often necessary to recognize tinea capitis in the adult population. Immunocompromised states or immunosuppression may predispose adults to develop tinea capitis.</p><p>Tinea capitis often can be diagnosed based upon the physical examination if there are alopecic patches with scaling or black dots consistent with tinea capitis. A potassium hydroxide (KOH) preparation or fungal culture should be performed to confirm tinea capitis if the diagnosis is in question. These tests are often particularly useful for patients with widespread scalp scaling and subtle hair loss because of the close resemblance to seborrheic dermatitis. Biopsy of the scalp is not typically necessary. (See <a class="local">'Potassium hydroxide preparation'</a> below and <a class="local">'Culture'</a> below.)</p><p>Polymerase chain reaction (PCR) testing has emerged as an alternative diagnostic test but is not routinely utilized for tinea capitis. (See <a class="local">'Other tests'</a> below.)</p><p class="headingAnchor" id="H420839875"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should include a careful examination of the hair and scalp to identify signs consistent with tinea capitis or suggestive of another disorder. Visualization of the characteristic "black dots" that can occur in endothrix tinea capitis or the classic scutula of favus are helpful signs that strongly suggest a diagnosis of tinea capitis. A localized inflamed, tender, boggy plaque on the scalp is suspicious for kerion. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Physical examination'</a>.)</p><p>Examination of the rest of the skin surface is also prudent to identify skin or nail findings suggestive of another condition. For example, psoriasis or seborrheic dermatitis often present with scalp disease associated with characteristic eruptions in other body areas. Cervical lymph nodes should be palpated because cervical lymphadenopathy is a common, though not ubiquitous finding in tinea capitis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Examination of the affected area with a Wood's light can help identify tinea capitis in patients with some ectothrix infections and favus. Ectothrix infections secondary to <em>M. canis</em> often exhibit green-yellow fluorescence under Wood's light illumination [<a href="#rid32">32</a>]. Wood's light illumination of favus secondary to <em>T. schoenleinii</em> reveals faint blue fluorescence [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1195733949"><span class="h2">Dermoscopy</span><span class="headingEndMark"> — </span>Dermoscopy of the hair and scalp (also known as trichoscopy) may be a useful adjunctive measure in the diagnosis of tinea capitis. Common dermoscopic findings in tinea capitis include broken hairs, dystrophic hairs, corkscrew hairs, comma hairs, and black dots  (<a class="graphic graphic_picture graphicRef90587" href="/z/d/graphic/90587.html" rel="external">picture 7</a>) [<a href="#rid33">33-36</a>]. The findings of a study of five children with tinea capitis suggest high magnification (x150) dermoscopy may identify additional features in tinea capitis, such as horizontal white bands in hair shafts (barcode-like hairs) and translucent, easily deformable hairs [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/13521.html" rel="external">"Overview of dermoscopy"</a>.)</p><p>A review of 24 children with tinea capitis suggests that dermoscopic findings may vary based upon the type of infection [<a href="#rid38">38</a>]. In addition to broken hairs and black dots, children with endothrix infections (eg, <em>T. tonsurans</em>, <em>T. soudanense</em>) exhibited comma hairs and corkscrew hairs, whereas children with ectothrix infections (eg, <em>M. canis</em>, <em>M. audouinii</em>) exhibited barcode-like hairs and zigzag hairs. Additional study is necessary to confirm these findings. </p><p class="headingAnchor" id="H420839882"><span class="h2">Potassium hydroxide preparation</span><span class="headingEndMark"> — </span>A potassium hydroxide (KOH) preparation is a rapid method for confirming the presence of a dermatophyte infection. Several hairs within the involved areas are plucked. The proximal ends of the hairs are then examined microscopically after application of potassium hydroxide to the slide. Arthroconidia (fungal spores) are found within the hair shaft in endothrix infections and predominantly outside of the hair shaft in ectothrix infections. KOH preparations of favus demonstrate hyphae and air spaces within hair shafts. Occasionally, KOH preparations fail to identify dermatophytes in patients with tinea capitis. (See  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p class="headingAnchor" id="H420839889"><span class="h2">Culture</span><span class="headingEndMark"> — </span>Fungal cultures are performed to confirm tinea capitis when the diagnosis is uncertain. However, because culture results may not be available for several weeks, if there is high suspicion for tinea capitis based upon the physical examination, treatment is usually begun empirically. False-negative results are common when fungal cultures are taken from kerion, likely secondary to the intense inflammatory response. Cultures taken during antifungal treatment of tinea capitis also are often negative, making it difficult to confirm the accuracy of the diagnosis.</p><p>To obtain a sample for culture, a sterile toothbrush is rubbed over the affected area, or the site is swabbed with a moistened cotton swab [<a href="#rid39">39-42</a>]. Sending some hairs with the scraping may increase the yield. Infected hairs often break and thus come out most easily. Culture can also be performed from a tissue biopsy; however, this is rarely necessary.</p><p>Occasionally, nondermatophyte fungi and yeasts, including <em>Alternaria</em>, <em>Aspergillus</em>, <em>Fusarium</em>, <em>Scopulariopsis</em>, or <em>Candida</em> species, are cultured from patients with clinical findings suggestive of tinea capitis [<a href="#rid43">43</a>]. In immunocompetent patients, it can be difficult to determine if these common environmental contaminants are truly acting as pathogens. In immunocompromised patients, molds can be important pathogens. If the diagnosis of tinea capitis is unclear (eg, if other causes of scalp scaling, such as sebopsoriasis or eczematous dermatitis, are suspected), then performing a repeat culture to prove the presence of a nondermatophyte fungus can be helpful. Absence of the same organism on repeat culture suggests a contaminant.</p><p class="headingAnchor" id="H49432547"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>PCR techniques, molecular tests that can be utilized to detect fungal DNA, have emerged as an additional option for confirming the presence of dermatophyte infections [<a href="#rid44">44</a>]. An advantage of PCR is the potential for more rapid detection and speciation of causative fungi compared with fungal culture. Factors such as cost and availability are limiting factors for PCR testing [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/4034.html" rel="external">"Onychomycosis: Epidemiology, clinical features, and diagnosis", section on 'Polymerase chain reaction'</a>.)</p><p class="headingAnchor" id="H949998265"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of tinea capitis primarily consists of other scalp disorders that may present with scale, pustules, or hair loss. The differential diagnosis varies according to the clinical presentation. A careful physical examination often reveals features that distinguish other diseases from tinea capitis. Identification of dermatophytes on a potassium hydroxide (KOH) preparation or culture also distinguishes tinea capitis from other diseases.</p><p>The differential diagnoses for tinea capitis based upon the clinical findings are reviewed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scaly patches with alopecia</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psoriasis </strong>– Well-demarcated, erythematous plaques with coarse scale are characteristic findings of psoriasis  (<a class="graphic graphic_picture graphicRef99443" href="/z/d/graphic/99443.html" rel="external">picture 8</a>). Often patients have skin involvement in other areas, such as the elbows, knees, or intertriginous areas. Nail abnormalities, such as pitting, discoloration, onycholysis, and subungual hyperkeratosis may be present. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patches of alopecia with black dots</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alopecia areata</strong> – Alopecia areata is an autoimmune form of hair loss that may occur in children and adults. Alopecia areata classically presents with discrete, often circular patches of alopecia  (<a class="graphic graphic_picture graphicRef71583 graphicRef87348" href="/z/d/graphic/71583.html" rel="external">picture 9A-B</a>). Scale is absent. Exclamation point hairs (short hairs up to a few millimeters in length with tapered proximal ends) are a common feature of alopecia areata that may be confused with broken hairs of tinea capitis  (<a class="graphic graphic_picture graphicRef65864" href="/z/d/graphic/65864.html" rel="external">picture 10</a>). (See  <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">"Alopecia areata: Clinical manifestations and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Widespread scaling with subtle hair loss</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seborrheic dermatitis</strong> – Seborrheic dermatitis of the scalp presents with diffuse scaling often associated with erythema and pruritus  (<a class="graphic graphic_picture graphicRef54173 graphicRef101268" href="/z/d/graphic/54173.html" rel="external">picture 11A-B</a>). Alopecia is typically absent. Patients may have involvement in other areas, such as the eyebrows, nasolabial folds, and intertriginous areas. Seborrheic dermatitis usually occurs in infants, adolescents, and adults. Prepubertal children usually do not develop seborrheic dermatitis. (See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/16261.html" rel="external">"Cradle cap and seborrheic dermatitis in infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kerion</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacterial folliculitis</strong> – The suppurative folliculitis that may be an early manifestation of kerion should be distinguished from bacterial folliculitis  (<a class="graphic graphic_picture graphicRef97630" href="/z/d/graphic/97630.html" rel="external">picture 12</a>). A Gram stain or culture will reveal the causative bacteria. (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Bacterial folliculitis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Folliculitis decalvans </strong>– Folliculitis decalvans is an uncommon form of cicatricial (scarring) alopecia that presents with one or more patches of alopecia with associated pustules. Follicular orifices typically are absent within the areas of alopecia, consistent with scarring. Tufted hairs (multiple hairs emerging from a single follicular orifice) are a common finding  (<a class="graphic graphic_picture graphicRef87489" href="/z/d/graphic/87489.html" rel="external">picture 13</a>). Unlike tinea capitis, folliculitis decalvans almost exclusively occurs in adults. Scalp biopsy confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15685.html" rel="external">"Folliculitis decalvans"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dissecting cellulitis </strong>–<strong> </strong>Dissecting cellulitis is an uncommon form of cicatricial alopecia characterized by the development of follicular papules, pustules, fluctuant nodules, and abscesses on the scalp  (<a class="graphic graphic_picture graphicRef91508" href="/z/d/graphic/91508.html" rel="external">picture 14</a>). Young Black men are the most common population affected. Biopsy confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15682.html" rel="external">"Dissecting cellulitis of the scalp"</a>.)</p><p></p><p>Recognition of the characteristic cup-shaped scutula strongly suggests a diagnosis of favus. In less-classic cases, disorders such as psoriasis  (<a class="graphic graphic_picture graphicRef99443" href="/z/d/graphic/99443.html" rel="external">picture 8</a>), discoid lupus  (<a class="graphic graphic_picture graphicRef99639" href="/z/d/graphic/99639.html" rel="external">picture 15</a>), pityriasis amiantacea  (<a class="graphic graphic_picture graphicRef58114" href="/z/d/graphic/58114.html" rel="external">picture 16</a>), and the cradle-cap presentation of seborrheic dermatitis  (<a class="graphic graphic_picture graphicRef101267" href="/z/d/graphic/101267.html" rel="external">picture 17</a>) may enter the differential diagnosis.</p><p>Other disorders that may enter the differential diagnosis of tinea capitis are trichotillomania (trichotillosis) and pediculosis capitis. Trichotillomania is a condition in which the patient manipulates or pulls the hair, often resulting in unusual configurations of hair loss  (<a class="graphic graphic_picture graphicRef96903" href="/z/d/graphic/96903.html" rel="external">picture 18</a>). Scale and inflammation is absent. The pruritus associated with pediculosis capitis may lead to suspicion for tinea capitis. However, the visualization of lice or nits on physical examination confirms pediculosis capitis  (<a class="graphic graphic_picture graphicRef65846" href="/z/d/graphic/65846.html" rel="external">picture 19</a>). In contrast to tinea capitis, scale is minimal or absent. (See  <a class="medical medical_review" href="/z/d/html/13698.html" rel="external">"Skin picking (excoriation) disorder and related disorders", section on 'Trichotillomania'</a>.)</p><p class="headingAnchor" id="H949998314"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Systemic antifungal treatment is the standard of care for children with tinea capitis. Special considerations for the treatment of kerion and infants and adults with tinea capitis are reviewed separately. (See <a class="local">'Treatment of special populations'</a> below.)</p><p class="headingAnchor" id="H1384652415"><span class="h2">Overview of treatment</span><span class="headingEndMark"> — </span>Treatment of tinea capitis begins once the diagnosis is made based upon the clinical evaluation and prior to the availability of culture results. If the diagnosis is likely tinea capitis, waiting until culture results have returned is not recommended because delaying treatment may increase risk for disease progression, permanent hair loss, and disease transmission.</p><p>Treatment should involve an oral antifungal agent that has demonstrated efficacy for tinea capitis. Topical antifungal therapy is unlikely to be effective because topical treatments have inadequate penetration of hair follicles and may miss sites of subclinical infection.</p><p>The systemic antifungal therapies for tinea capitis include <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a>, <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>. Griseofulvin has a long history of use for childhood tinea capitis and is a well-accepted first-line therapy. Terbinafine has emerged as an alternative first-line agent that may offer the advantage of shorter treatment courses. Fluconazole and itraconazole are effective but less frequently used than griseofulvin and terbinafine. Only griseofulvin and terbinafine have formulations that are approved by the US Food and Drug Administration (FDA) for the treatment of tinea capitis. (See <a class="local">'First-line therapy'</a> below and <a class="local">'Alternative therapies'</a> below.)</p><p>In the past, ionizing radiation was used for the treatment of tinea capitis. Treatment of tinea capitis with ionizing radiation is no longer recommended due to the potential for long-term side effects [<a href="#rid45">45</a>].</p><p>Adjunctive interventions for tinea capitis include use of a shampoo with antifungal properties to reduce risk of spread of infection to other individuals. Many clinicians, including ourselves, also encourage household members to use an antifungal shampoo to reduce risk for reinfection from continued contact with asymptomatic carriers. (See <a class="local">'Adjunctive interventions'</a> below and <a class="local">'Management of close contacts'</a> below.)</p><p>Children treated for tinea capitis require clinical follow-up to determine whether oral antifungal treatment can be discontinued or whether additional treatment is needed. (See <a class="local">'Prognosis and follow-up'</a> below.)</p><p class="headingAnchor" id="H949998320"><span class="h2">First-line therapy</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> and oral <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> are the most commonly used therapies for tinea capitis in children. Griseofulvin is a first-line therapy based upon the drug's efficacy in randomized trials and long history of use for this indication [<a href="#rid46">46</a>]. Terbinafine has emerged as an alternative first-line agent.  </p><p class="headingAnchor" id="H300274297"><span class="h3">Treatment selection</span><span class="headingEndMark"> — </span>Most patients with tinea capitis have <em>Trichophyton</em> or <em>Microsporum</em> infections. Randomized trial data are helpful for guiding treatment selection in these patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Trichophyton</em></strong><strong> infections</strong> – Both <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> and <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> are accepted first-line treatments for known or suspected <em>Trichophyton</em> tinea capitis. The use of terbinafine as an alternative first-line agent is a result of data demonstrating terbinafine is at least as effective as griseofulvin for <em>Trichophyton</em> infections, with shorter durations of treatment. In a meta-analysis of randomized trials, four weeks of terbinafine was as effective for achieving complete (clinical and mycologic) cure for <em>Trichophyton</em> infections as eight weeks of griseofulvin (risk ratio 1.06, 95% CI 0.98-1.15) [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1">There are data that suggest greater efficacy of <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> compared with <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> for some <em>Trichophyton</em> infections when given for similar duration. Pooled data from two randomized trials that compared a six-week course of terbinafine granules (5 to 8 mg/kg per day) with a six-week course of griseofulvin microsize (10 to 20 mg/kg per day) found similar efficacy for tinea capitis overall but greater efficacy of terbinafine for the subgroup of children with <em>T. tonsurans</em> infections (complete cure rate 52.1 versus 35.4 percent, risk ratio 1.47, 95% CI 1.22-1.77) [<a href="#rid47">47</a>]. There was no difference in effect for <em>T. violaceum</em> infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Microsporum</em></strong><strong> infections</strong> – <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">Griseofulvin</a> appears to be more effective for <em>Microsporum</em> infections than <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> and is preferred over terbinafine for known or suspected <em>Microsporum</em> infections. A systematic review and meta-analysis of randomized trials found a lower cure rate for <em>Microsporum</em> infections for a six-week course of terbinafine than for a 6- to 12-week course of griseofulvin (34.7 versus 50.9 percent, risk ratio 0.68, 95% CI 0.53-0.86) [<a href="#rid46">46</a>]. </p><p></p><p><a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">Griseofulvin</a> is first-line treatment for children in whom the cause of tinea capitis is unclear.</p><p class="headingAnchor" id="H1195734248"><span class="h3">Griseofulvin</span></p><p class="headingAnchor" id="H949998326"><span class="h4">Administration</span><span class="headingEndMark"> — </span>In the United States, <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> is available in a microsize formulation as tablets or a suspension. In addition, an ultramicrosize formulation is available as tablets.</p><p>Typical treatment regimens for children are:</p><p class="bulletIndent1"><span class="glyph">●</span>Microsize formulation – 20 to 25 mg/kg per day for 6 to 12 weeks [<a href="#rid48">48</a>]. The typical initial dose is 20 mg/kg per day for six to eight weeks. If there is partial response, the dose can be increased to 25 mg/kg per day and/or the length of therapy extended up to 12 weeks. The maximum daily dose is 1000 mg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ultramicrosize formulation – 10 to 15 mg/kg per day for 6 to 12 weeks [<a href="#rid48">48</a>]. The typical initial dose is 10 mg/kg per day for six to eight weeks. If there is partial response, the dose can be increased to 15 mg/kg per day and/or the length of therapy extended up to 12 weeks. The maximum daily dose is 750 mg per day.</p><p></p><p><a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">Griseofulvin</a> is absorbed more effectively when given with fatty food (eg, peanut butter, ice cream). Therapeutic failures are often due to lack of absorption.</p><p class="headingAnchor" id="H949998332"><span class="h4">Adverse effects and monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">Griseofulvin</a> typically is well tolerated. Gastrointestinal distress, headache, and cutaneous eruptions are potential side effects. Uncommon serious side effects include hepatotoxicity, granulocytopenia, leukopenia, and severe cutaneous reactions.</p><p>Laboratory evaluation prior to <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> treatment is not necessary. However, if therapy is continued beyond eight weeks or repeated courses of griseofulvin are given, liver function tests and a complete blood count should be obtained to evaluate for hepatic or hematologic toxicity.</p><p class="headingAnchor" id="H949998338"><span class="h3">Terbinafine</span></p><p class="headingAnchor" id="H1384652721"><span class="h4">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">Terbinafine</a> has very limited data for use in children under the age of four years. </p><p>Dosing for children is based upon weight. Typical pediatric dose regimens for <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> <strong>tablets</strong> are:</p><p class="bulletIndent1"><span class="glyph">●</span>10 to 20 kg – 62.5 mg daily for four to six weeks</p><p class="bulletIndent1"><span class="glyph">●</span>20 to 40 kg – 125 mg daily for four to six weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Above 40 kg – 250 mg daily for four to six weeks</p><p></p><p><a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">Terbinafine</a> tablets can be taken without regard to meals.</p><p>An alternative formulation of <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a>, terbinafine granules, is no longer available in the United States.</p><p class="headingAnchor" id="H949998350"><span class="h4">Adverse effects and monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">Terbinafine</a> therapy is usually well tolerated. Headache, gastrointestinal distress, taste disturbances, cutaneous eruptions, and liver enzyme abnormalities are potential side effects. Uncommon severe side effects include drug hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, serum sickness-like reaction, fulminant hepatic failure, drug-induced lupus, pancytopenia, and pancreatitis.</p><p>Liver function tests should be obtained prior to the start of <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> therapy. The tests should be repeated with the addition of a complete blood count if treatment extends beyond six weeks. Some clinicians do not obtain baseline liver function tests prior to treatment, given the rarity of preexisting liver disease in children and the typical short course of treatment with terbinafine.</p><p class="headingAnchor" id="H949998356"><span class="h2">Alternative therapies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> are effective, less frequently used treatments for tinea capitis. Compared with <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> and <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a>, efficacy data for fluconazole and itraconazole are more limited.</p><p><a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">Ketoconazole</a> should <strong>not </strong>be used for the treatment of tinea capitis. The drug is associated with risk for severe liver injury and adrenal insufficiency. </p><p class="headingAnchor" id="H420839314"><span class="h3">Fluconazole</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> can be effective for tinea capitis [<a href="#rid49">49,50</a>]. Randomized trials performed in populations where <em>Trichophyton</em> infections predominated have demonstrated similar efficacy between regimens of fluconazole and <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> [<a href="#rid49">49,51,52</a>]. In addition, a randomized trial that compared the efficacy of two to three weeks of treatment with fluconazole, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, or <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> and six weeks of treatment with griseofulvin for tinea capitis caused by <em>Trichophyton</em> species did not find significant differences in efficacy among these therapies.</p><p>Children can be treated with 6 mg/kg per day of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for three to six weeks [<a href="#rid53">53</a>]. The maximum daily dose is 400 mg. Data from a comparative study suggest that doses of 4 mg/kg may require longer durations of treatment than doses of 6 mg/kg [<a href="#rid54">54</a>]. Limited data suggest that once-<strong>weekly </strong>dosing of fluconazole also may be an effective treatment [<a href="#rid50">50,55</a>]. Children can be treated with a pulse dose of 6 mg/kg once weekly for 6 to 12 weeks. Some patients find the convenience of once-weekly dosing preferable despite the longer duration of treatment.</p><p><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> can lead to gastrointestinal distress, headache, cutaneous eruptions, and liver function test abnormalities. Uncommon serious side effects include hepatoxicity, severe drug hypersensitivity reactions (including Stevens-Johnson syndrome), anaphylaxis, Torsades de pointes, and prolongation of the QT interval.</p><p class="headingAnchor" id="H17874510"><span class="h3">Itraconazole</span><span class="headingEndMark"> — </span>Relatively few randomized trials have evaluated <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> for tinea capitis [<a href="#rid51">51,56,57</a>]. These trials have reported similar efficacy of two-week courses of itraconazole and <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> in children with tinea capitis caused by <em>Trichophyton</em> species [<a href="#rid57">57</a>] as well as similar efficacy between six-week courses of itraconazole and <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> in a trial population in which most patients had <em>M. canis</em> infections [<a href="#rid56">56</a>]. In addition, a randomized trial that compared the efficacy of two-week courses of itraconazole, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, or terbinafine (with an additional week of treatment as needed) and six-week courses of griseofulvin in children with tinea capitis caused by <em>Trichophyton</em> species did not find statistically significant differences in efficacy between the treatment groups [<a href="#rid51">51</a>].</p><p>The optimum regimen for <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> for tinea capitis is unclear. When used for tinea capitis in children, itraconazole is commonly prescribed at a dose of 3 to 5 mg/kg daily for four to six weeks. The maximum daily dose is 400 mg.</p><p>Pulse therapy also may be effective. Pulsed <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> is given at a dose of 5 mg/kg per day<strong> for one week each month</strong> for two to three months [<a href="#rid48">48,58</a>]. The suggested dose for pulse therapy with the oral solution of itraconazole is 3 mg/kg per day [<a href="#rid48">48</a>].</p><p>Potential side effects of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> include gastrointestinal distress, skin eruptions, headache, sleepiness, dizziness, and liver function test abnormalities. Liver function tests are indicated prior to treatment in patients with pre-existing hepatic dysfunction. These tests also should be obtained in patients treated for longer than one month.</p><p class="headingAnchor" id="H949998374"><span class="h2">Adjunctive interventions</span><span class="headingEndMark"> — </span>The management of tinea capitis should include measures to reduce spread of the infection and the likelihood of recurrence. We suggest that patients with tinea capitis use a shampoo with antifungal properties (eg, <a class="drug drug_general" data-topicid="9885" href="/z/d/drug information/9885.html" rel="external">selenium sulfide</a> 1 or 2.5%, <a class="drug drug_general" data-topicid="9263" href="/z/d/drug information/9263.html" rel="external">ciclopirox</a> 1%, or <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> 2% shampoo) at least twice weekly to decrease shedding of fungal spores [<a href="#rid59">59,60</a>]. Use of antifungal shampoo by other household members may also decrease the risk for reinfection (see <a class="local">'Management of close contacts'</a> below). It is also recommended that combs and hair trimming equipment be cleaned mechanically and disinfected (eg, with household bleach) [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H1195734171"><span class="h1">TREATMENT OF SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1384652361"><span class="h2">Kerion</span><span class="headingEndMark"> — </span>Oral antifungal therapy is the mainstay of treatment for kerion. Treatment regimens are similar to treatment for other forms of tinea capitis. (See <a class="local">'Treatment'</a> above.)</p><p>Systemic glucocorticoids (eg, 0.5 to 1 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for one week) are occasionally used in conjunction with antifungal therapy for patients with severe inflammation. However, it is unclear if the addition of a systemic glucocorticoid accelerates improvement or improves outcome [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H1195734178"><span class="h2">Infants</span><span class="headingEndMark"> — </span>Tinea capitis is uncommon in children under the age of one  (<a class="graphic graphic_picture graphicRef101271" href="/z/d/graphic/101271.html" rel="external">picture 1D</a>). Infants have been successfully treated with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a>, and <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> [<a href="#rid64">64-66</a>]. We typically treat with fluconazole, given the extensive experience with oral fluconazole therapy in infants for other indications.</p><p>Effective treatment with topical agents has been reported in infants [<a href="#rid64">64,66</a>]. However, data are insufficient to recommend routine use of topical therapy [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1195734306"><span class="h2">Adults</span><span class="headingEndMark"> — </span>The same medications are used for the treatment of children and adults with tinea capitis. The optimal treatment regimens for adults are unclear. Typical doses for adults are <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> 250 mg per day, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 5 mg/kg per day (maximum 400 mg per day), <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 6 mg/kg per day, and <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> ultramicrosize 10 to 15 mg/kg per day (maximum 750 mg per day) [<a href="#rid67">67</a>]. Treatment durations are similar to those used for children.</p><p class="headingAnchor" id="H1384653175"><span class="h1">MANAGEMENT OF CLOSE CONTACTS</span><span class="headingEndMark"> — </span>Household members of an individual diagnosed with tinea capitis should be physically examined for signs of tinea capitis and should be treated simultaneously if tinea capitis is detected.</p><p>Asymptomatic carriers of dermatophytes may serve as reservoirs for recurrent infection. Because of this possibility, we suggest use of an antifungal shampoo by all household members for two to four weeks [<a href="#rid68">68</a>]. Household members should begin to use the shampoo when the infected individual begins treatment for tinea capitis.</p><p>Children with tinea capitis should avoid sharing hair care tools and headwear (eg, helmets or hats) with other individuals. Pillowcases should not be shared. In addition, participation in sports with head-to-head contact should be avoided [<a href="#rid69">69</a>]. Bedding and towels used by the infected individual should be washed. Furniture that is frequently in direct contact with the affected individual or pet should be washed, if possible.</p><p>Cats or dogs (especially kittens and puppies) or other animals (such as cows, guinea pigs, and other animals) may be reservoirs for infection. The animals can have clinical signs of dermatophyte infection with scaling and hair loss, but can also be asymptomatic carriers. If there is an outbreak of tinea in a household, the pet (especially if new) should be evaluated by a veterinarian. The animal should also be evaluated if the patient or other household members experience recurrent dermatophyte infections [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H1540870637"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>The prognosis of tinea capitis is excellent, with complete clearance occurring in most patients after a course of treatment. Complete hair regrowth occurs in most children with hair loss. Patients with prolonged or severe infections (eg, kerion, favus) have the greatest risk for permanent alopecia. Still, the majority of lost hair often regrows.</p><p>There are rare reports of fungemia from dermatophyte infections in immunosuppressed patients. There is one report of culture-proven fungemia in an immunocompetent patient after surgical excision of a kerion due <em>T. mentagrophytes</em> [<a href="#rid71">71</a>].</p><p>Clinical follow-up to assess for clinical clearance should be performed at the end of therapy to assess for clinical cure. In patients who have experienced recurrent tinea capitis, we typically perform a fungal culture to confirm clearance after treatment. A fungal culture should also be performed in patients who appear to fail treatment. (See <a class="local">'Treatment failure'</a> below.)</p><p>Continuation of twice-weekly antifungal shampoo may help decrease the rate of reinfection.</p><p class="headingAnchor" id="H1540870631"><span class="h1">TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Signs of ongoing infection include persistent erythema, scale, or drainage. Hair loss may remain after successful treatment of tinea capitis, particularly in patients with kerion or favus. A fungal culture should be performed when patients appear to fail treatment. (See <a class="local">'Culture'</a> above.)</p><p>If there is a poor response to treatment, adherence to the treatment regimen should be assessed. This includes review of the actual frequency of treatment and dose ingested, as well the method of drug administration. <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">Griseofulvin</a> is much more effectively absorbed when given with fatty foods, and <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> absorption is reduced when crushed or sprinkled into apple sauce or fruits. If the child has been unable to take the medication as prescribed, methods to improve adherence (eg, education or change in medication formulation) should be made to increase the likelihood of adequate treatment.</p><p>For patients initially treated with 20 mg/kg of <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> per day and with good adherence to therapy, an inadequate response can be managed with an increase in dose to 25 mg/kg per day and extension of the treatment course to a total of 12 weeks. Alternatively, the patient can be switched to <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a>. Increasing the dose and duration of griseofulvin is our preferred intervention for patients with <em>M. canis</em> infection. Occasionally, treatment for longer than 12 weeks is needed. If a patient has a poor response to initial treatment with terbinafine, then griseofulvin should be used, especially if the infection is with <em>Microsporum</em> species.</p><p>In addition to adherence to therapy, the possibility of reinfection from contact with an infected individual or pet, contaminated fomites, or an asymptomatic carrier of the dermatophyte should be considered when patients fail treatment. (See <a class="local">'Management of close contacts'</a> above.)</p><p class="headingAnchor" id="H2325307493"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112069.html" rel="external">"Society guideline links: Dermatophyte infections"</a>.)</p><p class="headingAnchor" id="H949998399"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Tinea capitis is a common fungal infection of the scalp and hair that most commonly occurs in children. Dermatophytes in the genera <em>Trichophyton</em> and <em>Microsporum</em> are responsible for almost all cases of tinea capitis. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Forms of infection </strong>– Dermatophyte infection of the hair may present in three forms: endothrix infection, ectothrix infection, or favus. In endothrix infection, arthroconidia (fungal spores) are present within the hair shaft. Arthroconidia in ectothrix infections primarily surround the hair shaft. Favus is characterized by hyphae and air spaces within the hair shaft. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Tinea capitis has multiple clinical presentations. The most common manifestations are scaly patches with alopecia and patches of alopecia with black dots at follicular orifices that represent broken hairs  (<a class="graphic graphic_picture graphicRef86686 graphicRef101630 graphicRef101858 graphicRef101271 graphicRef101859 graphicRef86628" href="/z/d/graphic/86686.html" rel="external">picture 1A-F</a>). Other manifestations include widespread scaling on the scalp with subtle hair loss  (<a class="graphic graphic_picture graphicRef101860" href="/z/d/graphic/101860.html" rel="external">picture 4</a>), kerion (an inflammatory, boggy plaque  (<a class="graphic graphic_picture graphicRef86627" href="/z/d/graphic/86627.html" rel="external">picture 2</a>)), and favus  (<a class="graphic graphic_picture graphicRef101861" href="/z/d/graphic/101861.html" rel="external">picture 3</a>). Scutula (cup-shaped, yellow crusts) are a characteristic finding in favus. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Cervical lymphadenopathy is common in patients with tinea capitis. Secondary dermatitic eruptions (dermatophytid reactions) may also occur  (<a class="graphic graphic_picture graphicRef63421" href="/z/d/graphic/63421.html" rel="external">picture 6</a>). (See <a class="local">'Associated findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of tinea capitis may be made based upon clinical findings. A potassium hydroxide (KOH) preparation or fungal culture should be performed to confirm tinea capitis if the diagnosis is in question. Examination with a Wood's lamp and dermoscopy may be helpful for diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antifungal therapy </strong>– Oral antifungal therapy is the mainstay of antifungal therapy. Therapeutic options include <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a>, <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>Microsporum</em></strong><strong> tinea capitis </strong>– For patients with tinea capitis that is known or considered very likely to be secondary to <em>Microsporum</em> species, we recommend treatment with oral <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'First-line therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>Trichophyton </em></strong><strong>tinea capitis </strong>– For patients with tinea capitis that is known or very likely to be secondary to <em>Trichophyton</em> species, we suggest treatment with oral <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> based upon data indicating at least equivalent efficacy compared with <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a> with a shorter duration of treatment (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). (See <a class="local">'First-line therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjunctive measures and management of close contacts </strong>– Adjunctive measures for tinea capitis that may be of benefit include use of antifungal shampoos by the patient and household members. Use by the patient may reduce spread of the infection to others. Use by household members may reduce risk for reinfection secondary to continued contact with asymptomatic carriers. (See <a class="local">'Adjunctive interventions'</a> above and <a class="local">'Management of close contacts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up and recognition of treatment failure </strong>– Clinical follow-up is necessary for patients treated for tinea capitis to ensure adequate treatment. Signs of treatment failure include persistent erythema, scale, or drainage. Common causes of treatment failure include inconsistent or improper treatment administration or reinfection. Patients with recurrent tinea capitis may benefit from a fungal culture after treatment to confirm clearance of the infection. (See <a class="local">'Prognosis and follow-up'</a> above and <a class="local">'Treatment failure'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mirmirani P, Tucker LY. Epidemiologic trends in pediatric tinea capitis: a population-based study from Kaiser Permanente Northern California. J Am Acad Dermatol 2013; 69:916.</a></li><li><a class="nounderline abstract_t">Emele FE, Oyeka CA. Tinea capitis among primary school children in Anambra state of Nigeria. Mycoses 2008; 51:536.</a></li><li><a class="nounderline abstract_t">Fulgence KK, Abibatou K, Vincent D, et al. Tinea capitis in schoolchildren in southern Ivory Coast. Int J Dermatol 2013; 52:456.</a></li><li><a class="nounderline abstract_t">Mapelli ET, Cerri A, Bombonato C, Menni S. Tinea capitis in the paediatric population in Milan, Italy: the emergence of Trichophyton violaceum. Mycopathologia 2013; 176:243.</a></li><li><a class="nounderline abstract_t">Zampella JG, Kwatra SG, Blanck J, Cohen B. Tinea in Tots: Cases and Literature Review of Oral Antifungal Treatment of Tinea Capitis in Children under 2 Years of Age. J Pediatr 2017; 183:12.</a></li><li><a class="nounderline abstract_t">Zhan P, Geng C, Li Z, et al. Evolution of tinea capitis in the Nanchang area, Southern China: a 50-year survey (1965-2014). Mycoses 2015; 58:261.</a></li><li><a class="nounderline abstract_t">Keisham C, Sarkar R, Khurana N, et al. Black dot tinea capitis caused by trichophyton rubrum in an adult female presenting with cicatricial alopecia. Indian J Dermatol Venereol Leprol 2015; 81:224.</a></li><li><a class="nounderline abstract_t">El-Khalawany M, Shaaban D, Hassan H, et al. A multicenter clinicomycological study evaluating the spectrum of adult tinea capitis in Egypt. Acta Dermatovenerol Alp Pannonica Adriat 2013; 22:77.</a></li><li><a class="nounderline abstract_t">Mebazaa A, Oumari KE, Ghariani N, et al. Tinea capitis in adults in Tunisia. Int J Dermatol 2010; 49:513.</a></li><li><a class="nounderline abstract_t">Hillary T, Suys E. An outbreak of tinea capitis in elderly patients. Int J Dermatol 2014; 53:e101.</a></li><li><a class="nounderline abstract_t">Takwale A, Agarwal S, Holmes SC, Berth-Jones J. Tinea capitis in two elderly women: transmission at the hairdresser. Br J Dermatol 2001; 144:898.</a></li><li><a class="nounderline abstract_t">Abdel-Rahman SM, Farrand N, Schuenemann E, et al. The prevalence of infections with Trichophyton tonsurans in schoolchildren: the CAPITIS study. Pediatrics 2010; 125:966.</a></li><li><a class="nounderline abstract_t">Romano C. Case reports. Four paediatric cases of tinea capitis due to unusual agents. Mycoses 1999; 42:421.</a></li><li><a class="nounderline abstract_t">Lee WJ, Eun DH, Jang YH, et al. Tinea Faciei in a Mother and Daughter Caused by Arthroderma benhamiae. Ann Dermatol 2018; 30:241.</a></li><li><a class="nounderline abstract_t">Fuller LC, Child FC, Midgley G, Higgins EM. Scalp ringworm in south-east London and an analysis of a cohort of patients from a paediatric dermatology department. Br J Dermatol 2003; 148:985.</a></li><li><a class="nounderline abstract_t">Kelly BP. Superficial fungal infections. Pediatr Rev 2012; 33:e22.</a></li><li><a class="nounderline abstract_t">Fuller LC. Changing face of tinea capitis in Europe. Curr Opin Infect Dis 2009; 22:115.</a></li><li><a class="nounderline abstract_t">Kawachi Y, Ikegami M, Takase T, Otsuka F. Chronically recurrent and disseminated tinea faciei/corporis--autoinoculation from asymptomatic tinea capitis carriage. Pediatr Dermatol 2010; 27:527.</a></li><li><a class="nounderline abstract_t">Nenoff P, Krüger C, Ginter-Hanselmayer G, Tietz HJ. Mycology - an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges 2014; 12:188.</a></li><li><a class="nounderline abstract_t">Danielli LJ, Lopes W, Vainstein MH, et al. Biofilm formation by Microsporum canis. Clin Microbiol Infect 2017; 23:941.</a></li><li><a class="nounderline abstract_t">Mao L, Zhang L, Li H, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun 2014; 82:882.</a></li><li><a class="nounderline abstract_t">Shy R. Tinea corporis and tinea capitis. Pediatr Rev 2007; 28:164.</a></li><li><a class="nounderline abstract_t">Isa-Isa R, Arenas R, Isa M. Inflammatory tinea capitis: kerion, dermatophytic granuloma, and mycetoma. Clin Dermatol 2010; 28:133.</a></li><li><a class="nounderline abstract_t">Zaraa I, Hawilo A, Aounallah A, et al. Inflammatory Tinea capitis: a 12-year study and a review of the literature. Mycoses 2013; 56:110.</a></li><li><a class="nounderline abstract_t">Friedland R, Sabbah F, Reiss-Huss S, Ben Amitai D. Epidemiologic features and risk of scarring in pediatric patients with kerion celsi. Pediatr Dermatol 2022; 39:215.</a></li><li><a class="nounderline abstract_t">Ilkit M. Favus of the scalp: an overview and update. Mycopathologia 2010; 170:143.</a></li><li><a class="nounderline abstract_t">Cheng N, Rucker Wright D, Cohen BA. Dermatophytid in tinea capitis: rarely reported common phenomenon with clinical implications. Pediatrics 2011; 128:e453.</a></li><li><a class="nounderline abstract_t">Morrone A, Calcaterra R, Valenzano M, et al. Erythema nodosum induced by kerion celsi of the scalp in a woman. Mycoses 2011; 54:e237.</a></li><li><a class="nounderline abstract_t">Castriota M, Ricci F, Paradisi A, et al. Erythema nodosum induced by kerion celsi of the scalp in a child: a case report and mini-review of literature. Mycoses 2013; 56:200.</a></li><li><a class="nounderline abstract_t">Zaraa I, Trojjet S, El Guellali N, et al. Childhood erythema nodosum associated with kerion celsi: a case report and review of literature. Pediatr Dermatol 2012; 29:479.</a></li><li><a class="nounderline abstract_t">Patel GA, Schwartz RA. Tinea capitis: still an unsolved problem? Mycoses 2011; 54:183.</a></li><li><a class="nounderline abstract_t">Nenoff P, Krüger C, Schaller J, et al. Mycology - an update part 2: dermatomycoses: clinical picture and diagnostics. J Dtsch Dermatol Ges 2014; 12:749.</a></li><li><a class="nounderline abstract_t">Mapelli ET, Gualandri L, Cerri A, Menni S. Comma hairs in tinea capitis: a useful dermatoscopic sign for diagnosis of tinea capitis. Pediatr Dermatol 2012; 29:223.</a></li><li><a class="nounderline abstract_t">Ekiz O, Sen BB, Rifaioğlu EN, Balta I. Trichoscopy in paediatric patients with tinea capitis: a useful method to differentiate from alopecia areata. J Eur Acad Dermatol Venereol 2014; 28:1255.</a></li><li><a class="nounderline abstract_t">Slowinska M, Rudnicka L, Schwartz RA, et al. Comma hairs: a dermatoscopic marker for tinea capitis: a rapid diagnostic method. J Am Acad Dermatol 2008; 59:S77.</a></li><li><a class="nounderline abstract_t">Hughes R, Chiaverini C, Bahadoran P, Lacour JP. Corkscrew hair: a new dermoscopic sign for diagnosis of tinea capitis in black children. Arch Dermatol 2011; 147:355.</a></li><li><a class="nounderline abstract_t">Lacarrubba F, Verzì AE, Micali G. Newly described features resulting from high-magnification dermoscopy of tinea capitis. JAMA Dermatol 2015; 151:308.</a></li><li><a class="nounderline abstract_t">Bourezane Y, Bourezane Y. Analysis of trichoscopic signs observed in 24 patients presenting tinea capitis: Hypotheses based on physiopathology and proposed new classification. Ann Dermatol Venereol 2017; 144:490.</a></li><li><a class="nounderline abstract_t">Nasir S, Ralph N, O'Neill C, et al. Trends in tinea capitis in an Irish pediatric population and a comparison of scalp brushings versus scalp scrapings as methods of investigation. Pediatr Dermatol 2014; 31:622.</a></li><li><a class="nounderline abstract_t">Friedlander SF, Pickering B, Cunningham BB, et al. Use of the cotton swab method in diagnosing Tinea capitis. Pediatrics 1999; 104:276.</a></li><li><a class="nounderline abstract_t">Gupta AK, Mays RR, Versteeg SG, et al. Tinea capitis in children: a systematic review of management. J Eur Acad Dermatol Venereol 2018; 32:2264.</a></li><li><a class="nounderline abstract_t">Le M, Gabrielli S, Ghazawi FM, et al. Efficacies and merits of the cotton swab technique for diagnosing tinea capitis in the pediatric population. J Am Acad Dermatol 2020; 83:920.</a></li><li><a class="nounderline abstract_t">Moubasher AH, Abdel-Sater MA, Soliman Z. Incidence and biodiversity of yeasts, dermatophytes and non-dermatophytes in superficial skin infections in Assiut, Egypt. J Mycol Med 2017; 27:166.</a></li><li><a class="nounderline abstract_t">Wiegand C, Mugisha P, Mulyowa GK, et al. Identification of the causative dermatophyte of tinea capitis in children attending Mbarara Regional Referral Hospital in Uganda by PCR-ELISA and comparison with conventional mycological diagnostic methods. Med Mycol 2017; 55:660.</a></li><li><a class="nounderline abstract_t">Shvarts S, Sevo G, Tasic M, et al. The tinea capitis campaign in Serbia in the 1950s. Lancet Infect Dis 2010; 10:571.</a></li><li><a class="nounderline abstract_t">Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev 2016; :CD004685.</a></li><li><a class="nounderline abstract_t">Elewski BE, Cáceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol 2008; 59:41.</a></li><li><a class="nounderline abstract_t">Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166:353.</a></li><li><a class="nounderline abstract_t">Foster KW, Friedlander SF, Panzer H, et al. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol 2005; 53:798.</a></li><li><a class="nounderline abstract_t">Grover C, Arora P, Manchanda V. Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis. Int J Dermatol 2012; 51:455.</a></li><li><a class="nounderline abstract_t">Gupta AK, Adam P, Dlova N, et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 2001; 18:433.</a></li><li><a class="nounderline abstract_t">Dastghaib L, Azizzadeh M, Jafari P. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J Dermatolog Treat 2005; 16:43.</a></li><li class="breakAll">American Academy of Pediatrics. Committee on Infectious Diseases. Tinea capitis. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.778.</li><li><a class="nounderline abstract_t">Shemer A, Plotnik IB, Davidovici B, et al. Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study. J Dtsch Dermatol Ges 2013; 11:737.</a></li><li><a class="nounderline abstract_t">Gupta AK, Dlova N, Taborda P, et al. Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol 2000; 142:965.</a></li><li><a class="nounderline abstract_t">López-Gómez S, Del Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994; 33:743.</a></li><li><a class="nounderline abstract_t">Jahangir M, Hussain I, Ul Hasan M, Haroon TS. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998; 139:672.</a></li><li><a class="nounderline abstract_t">Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol 2000; 42:1.</a></li><li><a class="nounderline abstract_t">Chen C, Koch LH, Dice JE, et al. A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Pediatr Dermatol 2010; 27:459.</a></li><li><a class="nounderline abstract_t">Greer DL. Successful treatment of tinea capitis with 2% ketoconazole shampoo. Int J Dermatol 2000; 39:302.</a></li><li><a class="nounderline abstract_t">Winge MC, Chryssanthou E, Wahlgren CF. Combs and hair-trimming tools as reservoirs for dermatophytes in juvenile tinea capitis. Acta Derm Venereol 2009; 89:536.</a></li><li><a class="nounderline abstract_t">Keipert JA. Beneficial effect of corticosteroid therapy in microsporum canis kerion. Australas J Dermatol 1984; 25:127.</a></li><li><a class="nounderline abstract_t">Proudfoot LE, Higgins EM, Morris-Jones R. A retrospective study of the management of pediatric kerion in Trichophyton tonsurans infection. Pediatr Dermatol 2011; 28:655.</a></li><li><a class="nounderline abstract_t">Gilaberte Y, Rezusta A, Gil J, et al. Tinea capitis in infants in their first year of life. Br J Dermatol 2004; 151:886.</a></li><li><a class="nounderline abstract_t">Michaels BD, Del Rosso JQ. Tinea capitis in infants: recognition, evaluation, and management suggestions. J Clin Aesthet Dermatol 2012; 5:49.</a></li><li><a class="nounderline abstract_t">Zaraa I, Hawilo A, Trojjet S, et al. Letter: Tinea capitis in infants in their first 2 years of life: A 12-year study and a review of the literature. Dermatol Online J 2012; 18:16.</a></li><li class="breakAll">Elewski BE, Hughey LC, Sobera JO. Fungal diseases. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier Limited, 2012. Vol 2, p.1251.</li><li><a class="nounderline abstract_t">Graber MA, Randles BD, Monahan J, et al. What questions about patient care do physicians have during and after patient contact in the ED? The taxonomy of gaps in physician knowledge. Emerg Med J 2007; 24:703.</a></li><li><a class="nounderline abstract_t">Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. Am Fam Physician 2014; 90:702.</a></li><li><a class="nounderline abstract_t">Cafarchia C, Romito D, Capelli G, et al. Isolation of Microsporum canis from the hair coat of pet dogs and cats belonging to owners diagnosed with M. canis tinea corporis. Vet Dermatol 2006; 17:327.</a></li><li><a class="nounderline abstract_t">Rojat P, Hennequin C, Zaharia D, et al. Accidental Trichophyton mentagrophytes fungemia during the course of kerion celsi. Mycoses 2012; 55:e29.</a></li></ol></div><div id="topicVersionRevision">Topic 99983 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24094452" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiologic trends in pediatric tinea capitis: a population-based study from Kaiser Permanente Northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422917" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tinea capitis among primary school children in Anambra state of Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tinea capitis in schoolchildren in southern Ivory Coast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813120" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tinea capitis in the paediatric population in Milan, Italy: the emergence of Trichophyton violaceum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088394" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tinea in Tots: Cases and Literature Review of Oral Antifungal Treatment of Tinea Capitis in Children under 2 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756741" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evolution of tinea capitis in the Nanchang area, Southern China: a 50-year survey (1965-2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25751361" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Black dot tinea capitis caused by trichophyton rubrum in an adult female presenting with cicatricial alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336943" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A multicenter clinicomycological study evaluating the spectrum of adult tinea capitis in Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534084" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tinea capitis in adults in Tunisia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23488592" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An outbreak of tinea capitis in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298558" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tinea capitis in two elderly women: transmission at the hairdresser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403937" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The prevalence of infections with Trichophyton tonsurans in schoolchildren: the CAPITIS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10536435" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Case reports. Four paediatric cases of tinea capitis due to unusual agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29606829" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tinea Faciei in a Mother and Daughter Caused by Arthroderma benhamiae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786830" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Scalp ringworm in south-east London and an analysis of a cohort of patients from a paediatric dermatology department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474120" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Superficial fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19262376" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Changing face of tinea capitis in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20796239" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chronically recurrent and disseminated tinea faciei/corporis--autoinoculation from asymptomatic tinea capitis carriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24533779" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mycology - an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28642143" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Biofilm formation by Microsporum canis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24478101" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473121" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tinea corporis and tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347653" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inflammatory tinea capitis: kerion, dermatophytic granuloma, and mycetoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22757767" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inflammatory Tinea capitis: a 12-year study and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35028962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiologic features and risk of scarring in pediatric patients with kerion celsi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20411336" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Favus of the scalp: an overview and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21727102" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dermatophytid in tinea capitis: rarely reported common phenomenon with clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113399" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Erythema nodosum induced by kerion celsi of the scalp in a woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121556" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Erythema nodosum induced by kerion celsi of the scalp in a child: a case report and mini-review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692840" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Childhood erythema nodosum associated with kerion celsi: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002884" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tinea capitis: still an unsolved problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25176455" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mycology - an update part 2: dermatomycoses: clinical picture and diagnostics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22011204" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comma hairs in tinea capitis: a useful dermatoscopic sign for diagnosis of tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980908" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Trichoscopy in paediatric patients with tinea capitis: a useful method to differentiate from alopecia areata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19119131" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comma hairs: a dermatoscopic marker for tinea capitis: a rapid diagnostic method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422348" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Corkscrew hair: a new dermoscopic sign for diagnosis of tinea capitis in black children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471133" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Newly described features resulting from high-magnification dermoscopy of tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528735" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Analysis of trichoscopic signs observed in 24 patients presenting tinea capitis: Hypotheses based on physiopathology and proposed new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432351" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Trends in tinea capitis in an Irish pediatric population and a comparison of scalp brushings versus scalp scrapings as methods of investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10429007" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of the cotton swab method in diagnosing Tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29797669" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tinea capitis in children: a systematic review of management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31940462" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacies and merits of the cotton swab technique for diagnosing tinea capitis in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188051" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence and biodiversity of yeasts, dermatophytes and non-dermatophytes in superficial skin infections in Assiut, Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760831" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Identification of the causative dermatophyte of tinea capitis in children attending Mbarara Regional Referral Hospital in Uganda by PCR-ELISA and comparison with conventional mycological diagnostic methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20670904" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The tinea capitis campaign in Serbia in the 1950s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169520" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Systemic antifungal therapy for tinea capitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378354" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478357" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Update in antifungal therapy of dermatophytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243128" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435438" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737692" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897167" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897167" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23575220" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809856" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8002149" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892912" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607315" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tinea capitis: a current perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735804" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809984" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Successful treatment of tinea capitis with 2% ketoconazole shampoo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734990" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Combs and hair-trimming tools as reservoirs for dermatophytes in juvenile tinea capitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6534374" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Beneficial effect of corticosteroid therapy in microsporum canis kerion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082462" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A retrospective study of the management of pediatric kerion in Trichophyton tonsurans infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491432" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Tinea capitis in infants in their first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22468173" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tinea capitis in infants: recognition, evaluation, and management suggestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863638" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Letter: Tinea capitis in infants in their first 2 years of life: A 12-year study and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863638" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Letter: Tinea capitis in infants in their first 2 years of life: A 12-year study and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901270" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : What questions about patient care do physicians have during and after patient contact in the ED? The taxonomy of gaps in physician knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403034" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnosis and management of tinea infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961818" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Isolation of Microsporum canis from the hair coat of pet dogs and cats belonging to owners diagnosed with M. canis tinea corporis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21819454" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Accidental Trichophyton mentagrophytes fungemia during the course of kerion celsi.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
